AbbVie
Logotype for AbbVie Inc

AbbVie (ABBV) investor relations material

AbbVie Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for AbbVie Inc
Q3 2026 earnings summary30 Oct, 2026

Executive summary

  • Q3 net revenue was $17.404B, up 10.3% reported and 10.5% operational; adjusted diluted EPS was $3.82, versus $1.86 a year earlier.

  • Immunology and neuroscience led portfolio growth; FY26 revenue guidance rose by $200M and adjusted EPS guidance increased.

Financial highlights

  • GAAP operating earnings were $6.267B versus $1.904B, and GAAP net earnings were $4.218B versus $186M; GAAP diluted EPS was $2.37 versus $0.10.

  • Adjusted gross and operating margins were 85.1% and 48.7%; adjusted R&D and SG&A were 13.9% and 21.2% of sales.

  • Acquired IPR&D and milestone expense reduced Q3 adjusted diluted EPS by $0.11; adjusted results also excluded $1.669B of intangible amortization and $408M of acquisition and integration costs.

  • Nine-month revenue was $49.396B, up 10.9% reported and 10.1% operational; operating cash flow was $14.9B.

Outlook and guidance

  • FY26 revenue guidance rose $200M to $67.8B; adjusted EPS guidance increased to $13.95–$13.99, including $0.69 per share of acquired IPR&D and milestone expense incurred through Q3.

  • FY immunology sales outlook is $34.9B, including SKYRIZI at $21.8B and RINVOQ at $10.3B; neuroscience outlook is $13B.

  • FY oncology sales guidance is $6.6B and aesthetics outlook remains $5B; adjusted operating margin is forecast at ~46.7%.

  • Q4 revenue guidance is $18.4B and adjusted EPS guidance is $3.83–$3.87, excluding acquired IPR&D expense that may occur in the quarter.

  • 2027 guidance is expected on the Q4 call; management expects top-tier growth, with VRAYLAR IRA pricing beginning in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next AbbVie earnings date

Logotype for AbbVie Inc
Q4 20263 Feb, 2027
AbbVie
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next AbbVie earnings date

Logotype for AbbVie Inc
Q4 20263 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Innovative therapies for improved health worldwide

Abbvie is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's mission is to address complex health challenges and improve the lives of people around the world. Abbvie's primary areas of therapeutic focus include immunology, oncology, neuroscience, virology, and general medicine.

Abbvie's business model revolves around research and development (R&D) to discover and advance novel therapies, obtaining regulatory approvals for its products, and commercializing them in global markets. The company's revenue primarily comes from the sales of its pharmaceutical products.

Structural tailwinds

Opportunities for Abbvie lie in several areas. The global healthcare market continues to grow as the population ages, and there is a constant need for effective treatments for various diseases. Abbvie can leverage its R&D capabilities to develop innovative therapies that address unmet medical needs, expanding its product portfolio and capturing market share.

Furthermore, Abbvie has a robust pipeline of potential new drugs, which presents opportunities for future growth. By successfully developing and commercializing these pipeline candidates, the company can strengthen its market position and drive revenue growth.

Challenges faced by Abbvie include the competitive nature of the pharmaceutical industry. There are other established pharmaceutical companies and biotech firms developing treatments for similar indications. Abbvie needs to navigate patent expirations, competition from generic drugs, and the potential impact of biosimilars on its revenue.

Additionally, the regulatory environment poses challenges for Abbvie. Obtaining regulatory approvals for new drugs is a complex and time-consuming process, and the company must meet stringent safety and efficacy requirements set by regulatory authorities worldwide.

Three listed peers to Abbvie

Johnson & Johnson, a multinational healthcare conglomerate that operates in various segments, including pharmaceuticals, medical devices, and consumer health. It develops and sells a wide range of products and therapies across multiple therapeutic areas.

The leading global pharmaceutical company Pfizer that develops, manufactures, and markets a diverse portfolio of prescription drugs, vaccines, and consumer healthcare products. It has a strong presence in various therapeutic areas, including oncology, immunology, and rare diseases.

Eli Lilly and Company, a global pharmaceutical company that focuses on developing and commercializing innovative medicines in areas such as oncology, diabetes, neuroscience, and immunology. The company is known for its expertise in biotechnology and has a strong pipeline of potential new drugs.